GRASIM vs SUNPHARMA: Stock Comparison
SUN PHARMACEUTICAL IND L is the larger company by market capitalisation. SUN PHARMACEUTICAL IND L shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
GRASIM leads 3; SUNPHARMA leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GRASIM | SUNPHARMA |
|---|---|---|
| Sector | Construction Materials | Healthcare |
| Industry | Cement & Cement Products | Pharmaceuticals |
Price
| Metric | GRASIM | SUNPHARMA |
|---|---|---|
| Live Price | ₹2,894 | ₹1,748 |
| Day Change | -0.01% | -0.57% |
| Volume | 3.14 L | 10.65 L |
| 52-Week High | ₹3,411.1 | ₹2,046.9 |
| 52-Week Low | ₹2,502.5 | ₹1,583.7 |
| Distance from 52W High | -15.16% | -14.6% |
Valuation
| Metric | GRASIM | SUNPHARMA |
|---|---|---|
| Market Cap | ₹1.97 L Cr | ₹4.18 L Cr |
| P/E Ratio | 34.64x | 34.58x |
| P/B Ratio | 1.91x | 5x |
| EPS | ₹31.53 | ₹12.06 |
| Book Value | ₹2,495.89 | ₹349.6 |
| Dividend Yield | 0.35% | 0.92% |
Growth
| Metric | GRASIM | SUNPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | 10.5% | 12.8% |
| EPS Growth (TTM YoY) | 60.8% | 25.6% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | GRASIM | SUNPHARMA |
|---|---|---|
| ROE | 0.63% | 13.72% |
| ROCE | 1.57% | 15.16% |
| Net Margin | 2.83% | 18.56% |
| Operating Margin | 3.26% | 26.44% |
| Debt to Equity | 0.21x | 0.05x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | GRASIM | SUNPHARMA |
|---|---|---|
| Promoter Holding | 40.6%▲ 1.46 pp | 52.68%▼ 1.8 pp |
| FII Holding | 17.09%▼ 0.08 pp | 14.36%▼ 0.17 pp |
| DII Holding | 15.25%▼ 0.88 pp | 22.27%▲ 0.09 pp |
| Public Holding | 22.13%▼ 0.5 pp | 10.7%▲ 1.89 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GRASIM INDUSTRIES and SUN PHARMACEUTICAL IND L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.